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National Trends in Recurrent AMI Hospitalizations 1 Year After Acute
Myocardial Infarction in Medicare Beneﬁciaries: 1999–2010
Sarwat I. Chaudhry, MD; Rabeea F. Khan, BA; Jersey Chen, MD, MPH; Kumar Dharmarajan, MD, MBA; John A. Dodson, MD;
Frederick A. Masoudi, MD, MPH; Yun Wang, PhD; Harlan M. Krumholz, MD, SM
Background-—There are few data characterizing temporal changes in hospitalization for recurrent acute myocardial infarction (AMI)
after AMI.
Methods and Results-—Using a national sample of 2 305 441 Medicare beneﬁciaries hospitalized for AMI from 1999 to 2010, we
evaluated changes in the incidence of 1-year recurrent AMI hospitalization and mortality using Cox proportional hazards models.
The observed recurrent AMI hospitalization rate declined from 12.1% (95% CI 11.9 to 12.2) in 1999 to 8.9% (95% CI 8.8 to 9.1) in
2010, a relative decline of 26.4%. The observed recurrent AMI hospitalization rate declined by a relative 27.7% in whites, from
11.9% (95% CI 11.8 to 12.1) to 8.6% (95% CI 8.5 to 8.8) versus a relative decline in blacks of 13.6% from 13.2% (95% CI 12.6 to
13.8) to 11.4% (95% CI 10.9 to 12.0). The risk-adjusted rate of annual decline in recurrent AMI hospitalizations was 4.1% (HR
0.959; 95% CI 0.958 to 0.961), and whites experienced a higher rate of decline (HR 0.957, 95% CI 0.956 to 0.959) than blacks (HR
0.974, 95% CI 0.970 to 0.979).The overall, observed 1-year mortality rate after hospitalization for recurrent AMI declined from
32.4% in 1999 to 29.7% in 2010, a relative decline of 8.3% (P<0.05). In adjusted analyses, 1-year mortality after recurrent AMI
hospitalization declined 1.8% per year (HR, 0.982; 95% CI 0.980 to 0.985).
Conclusions-—In a national sample of Medicare beneﬁciaries hospitalized for AMI from 1999 to 2010, hospitalization for recurrent
AMI decreased, as did subsequent mortality, albeit to a lesser extent. The risk of recurrent AMI hospitalization declined less in
black patients than in whites, increasing observed racial disparities by the end of the study period. ( J Am Heart Assoc. 2014;3:
e001197 doi: 10.1161/JAHA.114.001197)
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Improvements in primary cardiovascular prevention,including control of hypertension, hyperlipidemia, and
cigarette smoking, have translated into substantial declines
in hospitalizations and deaths due to acute myocardial infarc-
tion (AMI) over the past decade.1 In contrast, there are few data
characterizing the incidence of hospitalization for recurrent
AMI. Previous studies of recurrent AMI have evaluated subjects
before the introduction of modern cardiovascular prevention
strategies2,3 or have been constrained to demographically and
geographically homogeneous populations.4–8 Increasing use of
routine revascularization for AMI9 and secondary prevention
therapies10–15 may have reduced rates of hospitalization for
recurrent AMI over the past decade. Conversely, improved AMI
survival rates may have created a population at higher risk of
hospitalization for recurrent AMI.16
Accordingly, we sought to examine recent national trends in
the occurrence and outcomes (ie, mortality) of recurrent AMI
hospitalization using a complete sample of fee-for-service
Medicare beneﬁciaries hospitalized for AMI from 1999 to 2010.
Medicare data provide sufﬁcient numbers to precisely estimate
changes in recurrent AMI hospitalization rates, and to examine
differences between relevant demographic subgroups. Com-
paring trends in recurrent AMI hospitalization rates between
age groups merits attention because older patients are at
particularly high risk for recurrent cardiovascular events.
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ORIGINAL RESEARCH
In addition, previous work evaluating recent temporal trends in
AMI hospitalization rates has shown that blackmen and women
experienced a lower decline in AMI hospitalization rate than
their white counterparts,1 but it is unknown whether such
differences also exist in recurrent AMI hospitalization rates.
These analyses can provide insight about whether contempo-
rary management strategies for AMI have resulted in decreas-
ing rates of recurrent AMI hospitalization, and whether these
gains have been shared equally across demographic subgroups.
Methods
Data Source
We used Medicare Provider Analysis and Review inpatient
data from the Centers for Medicare and Medicaid Services
to identify a complete sample of fee-for-service Medicare
beneﬁciaries who were hospitalized for AMI between January
1, 1999 and December 31, 2011. These administrative billing
claims data include information on patient demographics (age,
sex, and race), admission and discharge dates, and principal
and secondary diagnosis codes as coded by the International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁca-
tion. Medicare denominator ﬁles were used to ascertain
beneﬁciary eligibility, and enrollment in fee-for-service Medi-
care. Institutional Review Board review and approval was
obtained through the Yale University Human Investigation
Committee. Medicare claims data were provided through a
data use agreement with Centers for Medicare and Medicaid
Services.
Study Sample
Subjects were included if they were aged 65 years or older
and discharged alive from an acute care hospital with a
principal discharge diagnosis of AMI (International Classiﬁca-
tion of Diseases, Ninth Revision, Clinical Modiﬁcation code:
410.xx) between January 1, 1999 and December 31, 2010.
We identiﬁed the ﬁrst admission for AMI during the study
period as the “index AMI” hospitalization and the ﬁrst
subsequent AMI admission as the “recurrent AMI hospitaliza-
tion.” We excluded patients with principal discharge diagnosis
International Classiﬁcation of Diseases, Ninth Revision, Clin-
ical Modiﬁcation codes 410.x2, as these represent subse-
quent episodes of care related to the index AMI. Patients with
a total length of stay of ≤1 day were excluded, as those
hospitalizations are unlikely to represent true AMI. We also
excluded (1) beneﬁciaries aged <65 years; (2) beneﬁciaries
without ≥1 year of Medicare fee-for-service enrollment before
and after their index AMI hospitalization, as data would be
limited to assess comorbidity (see “Patient Characteristics”
section below) and outcomes; (3) beneﬁciaries with conﬂicting
dates of death and hospitalization; and (4) patients who were
subsequently transferred to another acute care hospital for
continuing care after an initial AMI. Patients who died during the
1-year follow up period without experiencing hospitalization for
recurrent AMI were censored at the time of death; all others
were censored at the end of the follow-up period.
Patient Characteristics
We used the Medicare Provider Analysis and Review data set
to collect information on patient characteristics, including
age, sex, race, and comorbidities. Race was determined from
the Medicare denominator ﬁles, which use patient-reported
data from the Social Security Administration. Coexisting
illnesses were classiﬁed according to the categorization used
by Centers for Medicare and Medicaid Services for the AMI
30-day mortality measure.17 We identiﬁed comorbidities from
both primary and secondary diagnosis codes of all patient
hospitalizations up to 1 year before the initial hospitalization
for AMI. For example, the inpatient data from 1998 were used
to obtain comorbidity information on patients who were
hospitalized for AMI in 1999.
Outcomes
Our ﬁrst study outcome was recurrent AMI within 1 year of
(admission for) the index AMI. Our second outcome was 1-
year all-cause mortality rates among patients who were
hospitalized for recurrent AMI.
Statistical Analysis
Baseline characteristics of patients hospitalized for AMI during
the study period were collapsed into 3-year intervals to simplify
presentation, and we used the Cochran–Armitage trend test to
examine the signiﬁcance of trends. We used Cox proportional
hazards regression models to assess annual trends in recurrent
AMI hospitalization rates, adjusting for age, sex, race, and all
comorbidities shown in Table. We ﬁtted separate Coxmodels to
analyze trends in recurrent AMI hospitalization rates among
subgroups (ie, age, sex, and race). All Cox models included an
ordinal time variable, ranging from 0 to 11, corresponding to
years 1999 (time=0) through 2010 (time=11) to represent the
risk-adjusted annual trend in 1-year recurrent AMI hospitaliza-
tions. Similarly, Cox proportional hazards regression models
were used to analyze 1-year mortality among patients who
experienced recurrent AMI hospitalization.
Y.W. conducted all analyses using SAS 9.3 64-bit version
(SAS Institute Inc, Cary, NC), and takes responsibility for the
accuracy of the results. Hazard ratios are reported with 95%
CI. Statistical tests were 2-sided at a signiﬁcance level of
0.05. The Yale University Human Investigation Committee
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During the 12-year study period, 3 067 263 patients experi-
enced an index AMI hospitalization. The number of patients who
experienced an index AMI hospitalization decreased from 1283
(95% CI 1278 to 1287) per 100 000 person-years in 1999 to
830 (95% CI 827 to 833) per 100 000 person-years in 2010.
Among patients who experienced an index AMI hospitalization,
2 305 441 were enrolled continuously in the Medicare fee-for-
service program for at least 12 months before and 12 months
following (in the absence of death) the index AMI hospitaliza-
tion, were discharged alive after at least 1 day, and were not
transferred to another short-term acute-care hospital.
Table. Patient Characteristics
Characteristics 1999–2001 2002–2004 2005–2007 2008–2010 Cumulative
Total 592 255 631 114 565 082 516 990 2 305 441
Age in years, mean (SD) 78.8 (7.8) 78.8 (8.1) 78.9 (8.3) 78.9 (8.5) 78.8 (8.2)
Female, n (%) 303 715 (51.3) 321 297 (50.9) 282 310 (50.0) 254 543 (49.2) 1 161 865 (50.4)
White, n (%) 525 818 (88.8) 555 212 (88.0) 496 067 (87.8) 452 153 (87.5) 2 029 250 (88.0)
Black, n (%) 42 645 (7.2) 47 188 (7.5) 43 024 (7.6) 40 325 (7.8) 173 182 (7.5)
Other race, n (%) 23 792 (4.0) 28 714 (4.5) 25 991 (4.6) 24 512 (4.7) 103 009 (4.5)
Comorbidity, n (%)
Coronary artery disease 413 276 (69.8) 459 239 (72.8) 415 081 (73.5) 383 472 (74.2) 1 671 068 (72.5)
Hypertension 326 468 (55.1) 373 051 (59.1) 344 592 (61.0) 343 818 (66.5) 1 387 929 (60.2)
Diabetes 182 534 (30.8) 199 071 (31.5) 177 807 (31.5) 164 339 (31.8) 723 751 (31.4)
COPD 135 963 (23.0) 152 168 (24.1) 139 223 (24.6) 106 540 (20.6) 533 894 (23.2)
Congestive heart failure 95 656 (16.1) 102 466 (16.2) 90 212 (16.0) 79 159 (15.3) 367 493 (15.9)
Pneumonia 73 783 (12.5) 87 483 (13.9) 81 442 (14.4) 79 956 (15.5) 322 664 (14.0)
Dementia 56 303 (9.5) 66 764 (10.6) 60 434 (10.7) 58 597 (11.3) 242 098 (10.5)
Renal failure 27 923 (4.7) 38 572 (6.1) 54 477 (9.6) 66 316 (12.8) 187 288 (8.1)
Peripheral vascular disease 38 715 (6.5) 44 107 (7.0) 39 733 (7.0) 35 977 (7.0) 158 532 (6.9)
Cancer 37 070 (6.3) 40 736 (6.5) 37 047 (6.6) 34 393 (6.7) 149 246 (6.5)
Trauma 31 268 (5.3) 38 071 (6.0) 36 030 (6.4) 32 167 (6.2) 137 536 (6.0)
Depression 27 372 (4.6) 34 267 (5.4) 30 676 (5.4) 28 552 (5.5) 120 867 (5.2)
History of MI 29 546 (5.0) 32 848 (5.2) 27 353 (4.8) 26 107 (5.0) 115 854 (5.0)
Cerebrovascular disease 33 581 (5.7) 32 471 (5.1) 25 257 (4.5) 22 256 (4.3) 113 565 (4.9)
Unstable angina 36 748 (6.2) 31 937 (5.1) 22 021 (3.9) 17 102 (3.3) 107 808 (4.7)
Respiratory failure 15 475 (2.6) 17 774 (2.8) 20 445 (3.6) 25 121 (4.9) 78 815 (3.4)
Malnutrition 13 212 (2.2) 16 266 (2.6) 17 528 (3.1) 23 703 (4.6) 70 709 (3.1)
Functional disability 15 897 (2.7) 16 246 (2.6) 12 807 (2.3) 13 409 (2.6) 58 359 (2.5)
Stroke 12 731 (2.1) 12 653 (2.0) 10 802 (1.9) 9649 (1.9) 45 835 (2.0)
Psychiatric disease 11 536 (1.9) 12 202 (1.9) 10 029 (1.8) 10 877 (2.1) 44 644 (1.9)
Liver disease 2980 (0.5) 3730 (0.6) 3566 (0.6) 3291 (0.6) 13 567 (0.6)
Length of stay, mean (SD) 7.1 (6.2) 6.8 (6.2) 6.4 (5.9) 5.9 (5.4) 6.5 (5.4)
Discharged to home, n (%) 367 198 (62.0) 365 415 (57.9) 314 186 (55.6) 286 929 (55.5) 1 332 545 (57.8)
Discharged to ICF/SNF, n (%) 114 897 (19.4) 126 223 (20.0) 115 842 (20.5) 102 881 (19.9) 461 088 (20.0)
Discharged to home care, n (%) 76 993 (13.0) 89 618 (14.2) 89 283 (15.8) 81 684 (15.8) 336 594 (14.6)
Discharged to hospice, n (%) 148 064 (0.25) 8836 (1.4) 14 692 (2.6) 17 061 (3.3) 41 498 (1.8)
COPD indicates chronic obstructive pulmonary disease; MI, myocardial infarction; ICF, intermediate care facility; SNF, skilled nursing facility.
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The characteristics of the patients in the ﬁnal study sample
are presented in Table. The mean age was 78.8 years (SD
8.2 years), 50.4% were women, and 12.0% were of nonwhite
race. The most common comorbidities were coronary artery
disease (72.5%), hypertension (60.2%), diabetes (31.4%),
chronic obstructive pulmonary disease (COPD) (23.2%), and
heart failure (15.9%).
There were several notable (and statistically signiﬁcant,
P<0.05) changes in the characteristics of patients hospital-
ized for AMI during the 12-year study period. The percent-
age of females decreased from 51.1% in 1999 to 48.8% in
2010, and the percentage of nonwhites increased from
11.0% to 12.7%. The prevalence of a diagnosis of coronary
artery disease prior to the index MI and hypertension both
increased over the study period, from 68.3% to 74.1% and
53.1% to 66.9%, respectively. The prevalence of renal failure
also increased notably from 4.2% to 13.5%. The mean
length of stay decreased from 7.2 days (SD 6.2 days) in
1999 to 5.6 days (SD 5.3 days) in 2010. The percentage of
patients discharged to home decreased over the study
period (62.6% to 56.0%), while the percentage of patients
discharged to home care increased (13.4% to 15.9%).
Among participants who did not experience a recurrent AMI
hospitalization during the year following an initial AMI
hospitalization, the 1-year mortality declined from 21.7%
(95% CI, 21.6 to 21.9) in 1999 to 21.1% (95% CI, 20.9 to
21.3) in 2010.
One-Year Recurrent AMI Hospitalization Rate
The overall (during the entire study period) 1-year recur-
rent AMI hospitalization rate was 10.1% (95% CI 10.0 to
10.1). The mean number of days until readmission for
recurrent AMI increased from 108 in 1999 to 117 in 2010
(P<0.05).
The observed (ie, unadjusted) annual recurrent AMI
hospitalization rate declined from 12.1% (95% CI 11.9 to
12.2) in 1999 to 8.9% (95% CI 8.8 to 9.1) in 2010, a relative
decline of 26.4% (Figure 1). The mean, relative annual decline
was 2.4%. The decline in recurrent AMI hospitalization rate
was observed among all demographic subgroups (Figure 1).
Throughout the study period, the lowest recurrent AMI
hospitalization rate was observed in those 65 to 74 years
old (9.5%, 95% CI 9.2 to 9.7). Although a decline in recurrent
AMI hospitalization rate was observed in both males and
females, females consistently had a higher rate of recurrent
AMI hospitalization than males over the course of the study
period. The recurrent AMI hospitalization rate declined by a
relative 27.0% in females, from 12.6% (95% CI 12.4 to 12.9) in
1999 to 9.2% 95% CI 9.0 to 9.5) in 2010, and by 25.2% in
males, from 11.5% (95% CI 11.3 to 11.7) in 1999 to 8.6%
(95% CI 8.4 to 8.8) in 2010. When compared by race, the
reduction in recurrent AMI hospitalization rate was larger in
whites than blacks. The recurrent AMI hospitalization rate
declined by a relative 27.7% in whites, from 11.9% (95% CI
Figure 1. Observed 1-year rates of recurrent acute myocardial infarction (AMI) hospitalization.
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11.8 to 12.1) to 8.6% (95% CI 8.5 to 8.8) versus a relative
decline in blacks of 13.6% from 13.2% (95% CI 12.6 to 13.8)
to 11.4% (95% CI 10.9 to 12.0). The discrepancy between
recurrent AMI hospitalization rates in whites and blacks
was therefore higher by the end of the study period (ie,
8.6% versus 11.4%) compared with the beginning (11.9%
versus 13.2%).
As shown in Figure 2, after adjusting for demographic
and clinical covariates, the overall risk-adjusted rate of
annual decline in recurrent AMI hospitalizations was 4.1%,
corresponding to a HR of 0.959 (95% CI 0.958 to 0.961).
The rate of annual decline was highest among those 75 to
84 years of age, HR 0.953 (95% CI 0.951 to 0.955). While
males and females had similar adjusted rates of decline in
recurrent AMI hospitalization, whites experienced a statis-
tically signiﬁcantly higher rate of decline (HR 0.957, 95% CI
0.956 to 0.959) than black patients (HR 0.974, 95% CI
0.970 to 0.979).
1-Year All-Cause Mortality After Recurrent AMI
Hospitalization
The overall, observed 1-year mortality rate after hospitaliza-
tion for recurrent AMI declined from 32.4% in 1999 to 29.7%
in 2010, a relative decline of 8.3% (P<0.05) (Figure 3). Within
age subgroups, the decline in 1-year mortality was greatest
among those 75 to 84 years of age, declining relatively 16.4%,
from 31.7% in 1999 to 26.5% in 2010 (P<0.05). Declines in 1-
year mortality were observed across both sexes and all races.
Consistently higher 1-year mortality rates were observed in
females compared with males: 30.8% versus 28.5% by 2010
(P<0.0001).
In adjusted analyses, (Figure 4) the 1-year mortality
declined 1.8% per year (HR 0.982 [95% CI 0.980 to 0.985]).
Among the age subgroups, the lowest rate of decline was
observed in those over 85 years of age (HR 0.988 [95% CI
0.984 to 0.993]). Adjusted rates of mortality decline were
similar in both sexes and in all racial groups.
Figure 3. Observed 1-year rates of mortality.
Figure 2. Risk-adjusted annual trends in reinfarction rates. Cox
proportional hazards regression models were used to assess
annual trends in recurrent acute myocardial infarction (AMI)
hospitalization rates, adjusting for age, sex, race, and all
comorbidities shown in Table.
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In a national sample of Medicare fee-for-service beneﬁciaries,
we found that the incidence of recurrent AMI hospitalization
declined substantially from 1999 to 2010. The overall risk-
adjusted rate of annual decline in recurrent AMI hospitaliza-
tions was 4.1%. Declines were seen in all demographic
groups, but blacks had less decline in recurrent AMI
hospitalizations as compared with whites. Females and those
in the oldest age group (85 years and older) remained at
higher risk for recurrent AMI hospitalization throughout the
study period, compared with males and younger persons,
respectively. When considering risk-adjusted mortality after
hospitalization for recurrent AMI, there was an annual decline
of 1.8%, and females again had persistently higher mortality
than males.
Our analysis extends prior work examining temporal trends
in recurrent AMI hospitalization rates. A Swedish study found
an adjusted decrease in average risk of 2.5% per calendar
year for women and 3.1% for men for recurrent AMI from
1972 to 2001.4 A decline of 5.9% per year in the rate of
recurrent AMI was observed in the Danish MONICA population
from 1982 to 1991,5 and similar decreases in the rate of
recurrent AMI were observed during this time period in
Iceland6 and Finland.7,8 In the United States, a decline in
annual rate of recurrent AMI in men (2.6% per year) and
women (1.9% per year) was reported between 1987 and 1994
in 4 different United States communities in the ARIC
study.18,19 Notably, these previous studies do not include
contemporary data from a racially diverse population. To our
knowledge, our study is the ﬁrst to examine changes in the
rate of hospitalization for recurrent AMI after AMI over the last
decade using US-based national data.
Although we cannot identify the speciﬁc reasons for the
decline in recurrent AMI hospitalizations and 1-year mortality
rates, several theories might explain these observations. One
possible explanation is that the improvements may reﬂect the
implementation of secondary prevention as recommended by
the American College of Cardiology and American Heart
Association, including increasing use of aspirin, b-blockers,
angiotensin converting enzyme inhibitors, thienopyridines,
and statins.20–25 A study based on the Global Registry of
Acute Coronary Events, which includes data from 113
hospitals across 14 countries, reported that use of these
medications increased in AMI patients from 23% in 2000 to
58% in 2005,25 ﬁndings similar to the increases reported in
the Worcester, Mass study from 1995 to 2005.23 Further-
more, the use of percutaneous coronary intervention has
increased substantially over the last decade, which may also
have contributed to improved outcomes. A recent study based
on the United States Nationwide Inpatient Sample database,
an all-payer inpatient care database from 1000 hospitals,
reported that percutaneous coronary intervention for ST-
segment elevation myocardial infarction increased by 33.5%
among patients aged 65 to 79 and 22% in patients >80 years
of age in the United States from 2001 to 2010.26 Of note, the
observed decrease in recurrent AMI hospitalizations occurred
despite the increasing use of high-sensitivity troponin assays
to diagnose AMI over the study period. It is possible that the
observed decrease would have been even greater if laboratory
assays for AMI diagnosis had not changed.
While the overall declines in recurrent AMI hospitalization
and subsequent mortality rates over the past decade are
encouraging, not all groups beneﬁtted equally from improve-
ments in recurrent AMI hospitalizations. When compared by
race, the reduction in observed, recurrent AMI hospitalization
rate in whites was double that seen in blacks, with a relative
decline of 27.7% versus 13.6% from 1999 to 2010 (P<0.05).
Racial disparities in recurrent AMI hospitalization rates
thereby actually widened over the study period. The explana-
tion for the attenuated decline observed in black patients is
likely multifactorial. A higher prevalence of cardiac risk factors
(hypertension, diabetes, smoking, obesity), as well as socio-
economic factors (ie, healthcare access, insurance) leading to
differences in quality of care have been linked to worse
outcomes in blacks as compared to whites.27–30 As multivar-
iable models were constructed separately for each demo-
graphic subgroup, it is possible that differences in cardiac risk
factors contributed to the differences observed between
blacks and whites in recurrent AMI hospitalization rates.
Furthermore, some evidence suggests that nonwhite race is a
risk factor for nonadherence to recommended American
College of Cardiology/American Heart Association guidelines
for treatment of AMI.31–34 A study of AMI patients in the
1992–2003 Medicare Current Beneﬁciary Survey reported
Figure 4. Risk-adjusted annual trends in 1-year mortality. Cox
proportional hazards regression models were used to assess
annual trends in mortality rates, adjusting for age, sex, race, and
all comorbidities shown in Table. AMI indicates acute myocardial
infarction.
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that while overall combination drug therapy increased over
the study period, nonwhite race was independently associated
with suboptimal treatment.34 Notably, mortality rates were
similar in blacks and whites, making differential censoring an
unlikely explanation for the differences in recurrent AMI
hospitalization.
There are several potential limitations in our study. Our
data are based on the Medicare fee-for-service population,
and trends in recurrent AMI hospitalizations may differ in
younger patients or those with different health insurance.
Because we relied on administrative data, we were also not
able to obtain detailed clinical information about risk factor
proﬁles (eg, cigarette smoking), mechanism of recurrent MI
(eg, stent thrombosis), and cause of death. Comorbidities
were ascertained from administrative codes and not clinically
conﬁrmed, and hospitals may have changed patterns of
medical coding over time. Finally, we used a linear model to
examine changes in recurrent AMI rates. The decline in
recurrent AMI appears to diminish in the ﬁnal years of the
study period, and future studies are needed to determine
whether there is continuing decline in recent years.
Conclusions
In a national cohort of Medicare patients, the risk-adjusted
rate of annual decline in recurrent AMI hospitalizations was
4.1% from 1999 to 2010. The risk-adjusted rate of annual
decline in mortality within 1 year after recurrent AMI hospi-
talization was 1.8% during this period. Improvements in
recurrent AMI hospitalization rates were signiﬁcantly attenu-
ated in black patients, resulting in widened racial disparities
by the end of the study period. Future work should examine
strategies to ensure that gains realized in post-AMI outcomes
can be shared equally among all patients, regardless of race.
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